On January 7, Soley Therapeutics announced a $200 million Series C financing to advance its proprietary cell stress sensing platform and advance two first-in-class, internally discovered oncology assets toward the clinic, including a lead acute myeloid leukemia (AML) program on track for an IND filing in 2026, alongside continued work on stress-reducing candidates targeting neurodegenerative disorders and metabolic diseases and ongoing platform scale-up.
This Series C financing was led by Surveyor Capital (a Citadel Company) as primary investor, joined by new investors HRTG Partners and RWN Management and others. Existing Soley investors, including Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investment® LP, and other undisclosed investors also participated.
The financing will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, including the AML program on track for an IND filing in 2026 and a second asset for solid tumor(s) entering IND-enabling studies, while also supporting continued platform scale-up and advancement of non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases.
In simple terms, Soley’s approach treats living human cells like highly sensitive sensors. The company measures how cells react under stress and after exposure to potential drugs, then uses imaging and AI to translate those reactions into signals that help identify and design new medicines.
The Soley platform captures time-resolved responses across thousands of features in human cells, then uses proprietary computer vision and AI to convert those features into compact, structured signatures. It screens hundreds of thousands of compounds per week, generates reproducible data at scale in-house using first-in-class automation and robotics, and trains proprietary AI/ML models, to accelerate hit finding, mechanistic insights, and molecule design.
Soley describes two main directions for the same platform. In oncology, it seeks compounds that selectively intensify stress inside cancer cells to push them toward death while filtering out broadly toxic molecules early. Outside oncology, it looks for compounds that help restore healthier cell states in diseases marked by cellular exhaustion or stress dysregulation.
“We built Soley to measure how living human cells, in health and disease, respond to drug exposure and determine their fate. We then translate this cellular information into a robust portfolio of novel drug candidates across a broad range of disease areas and indications,” said Yerem Yeghiazarians, M.D., Co-Founder and CEO of Soley Therapeutics. “We are thrilled by the strong investor support from life sciences and technology focused funds as we advance our lead programs into the clinic and expand our platform to continue building a first-in-class pipeline.”
About Soley Therapeutics
Soley Therapeutics is a science-first, tech-enabled drug discovery and development company using cells as the world’s most powerful sensors to uncover first-in-class medicines. Soley’s platform translates the cellular information of stress biology into mechanistic insight, revealing novel drug candidates that otherwise would be missed. Soley deploys full-stack AI via its collaboration with Oracle, including OCI AI Infrastructure, NVIDIA AI Enterprise and NVIDIA Blackwell GPUs. By combining foundational biology, proprietary imaging, first-in-class automation, and integrated AI tools, Soley has rapidly built a pipeline that spans oncology, neurodegenerative disorders, metabolic diseases, and other areas. Soley is headquartered in South San Francisco.
Soley also says its platform is built on decades of foundational research and 130+ publications, and that in under three years it has produced more than a dozen proprietary chemical series and numerous drug-like compounds, with medicines it advances discovered in-house and described as novel and patentable.
